Clinical Trials Browser

Phase 1/2 × atezolizumab × Gastrointestinal × Clear all

NCT07291076 2026-04-14

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05440708 2026-04-06

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05468359 2026-03-16

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT02705196 2026-02-24

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Phase 1/2 Completed

Gastrointestinal

Adenoviridae Infections, Neoplasms, Pancreatic Neoplasms

NCT03942328 2026-02-24

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT07280377 2025-12-12

GOBLET

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

NCT05908786 2025-12-11

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05052099 2025-09-29

COMBATBIL

Phase 1/2 Completed

Gastrointestinal

Biliary Tract Neoplasms

NCT06294548 2025-08-11

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04166721 2025-04-06

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1/2 Terminated

222 enrolled 49 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03127007 2025-01-22

R-IMMUNE

Phase 1/2 Completed

Gastrointestinal

Rectal Neoplasms

NCT04440735 2025-01-09

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04214418 2024-12-18

MEKiAUTO

Phase 1/2 Terminated

27 enrolled 12 charts

Gastrointestinal

Gastrointestinal Neoplasms

NCT06584071 2024-12-16

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Phase 1/2 Not yet recruiting

Gastrointestinal

Liver Neoplasms

NCT06725121 2024-12-16

MacroTrans

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06006286 2024-08-26

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT03555149 2023-11-07

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Phase 1/2 Terminated

96 enrolled 24 charts

Gastrointestinal

Colorectal Neoplasms

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT05109052 2023-07-13

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms